Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.47 |
| ▸ | ESR1 | P03372 | 6/20 | 0.47 |
| ▸ | TYR | P14679 | 2/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69172 | 0.83 | ESR2 (0.49) | ESR2ESR1TYRHSD17B1CYP3A4 | |
| SCHEMBL8752791 | 0.83 | TYR (0.58) | ESR2ESR1TYRCYP3A4CHRM1 | |
| SCHEMBL1665310 | 0.81 | SHBG (0.47) | ESR2ESR1TYRHSD17B1CYP3A4 | |
| SCHEMBL31305640 | 0.81 | ESR2 (0.47) | ESR2ESR1TYRHSD17B1CYP3A4 | |
| SCHEMBL2018825 | 0.81 | ESR2 (0.47) | ESR2ESR1TYRHSD17B1CYP3A4 | |
| SCHEMBL4394169 | 0.79 | ESR2 (0.46) | ESR2ESR1TYRHSD17B1CYP3A4 | |
| SCHEMBL11243543 | 0.79 | ESR2 (0.46) | ESR2ESR1TYRHSD17B1CYP3A4 | |
| SCHEMBL10306731 | 0.79 | ESR2 (0.46) | ESR2ESR1TYRHSD17B1CYP3A4 | |
| SCHEMBL18179322 | 0.79 | ESR2 (0.46) | ESR2ESR1TYRHSD17B1CYP3A4 | |
| SCHEMBL95787 | 0.78 | TP53 (0.48) | SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341503-B1 | AGENT AND METHOD FOR DYEING KERATIN FIBRES | WELLA AG (DE) | 2008-02-13 | — | — | EP | claimed |
| US-5510420-A | NUCLEOPHILIC GRAFTING OF PARENT POLYMER HAVING AROMATIC RINGS CONTAINING REACTIVE GROUPS | HOECHST CELANESE CORPORATION (US) | 1996-04-23 | — | — | US | claimed |
| EP-0686274-A1 | NOVEL MATRIX RESIN FOR HIGH-TEMPERATURE STABLE PHOTOIMAGEABLE COMPOSITIONS | HOECHST CELANESE CORPORATION (US) | 1995-12-13 | — | — | EP | claimed |
| WO-1994019724-A1 | NOVEL MATRIX RESIN FOR HIGH-TEMPERATURE STABLE PHOTOIMAGEABLE COMPOSITIONS | HOECHST CELANESE CORPORATION (US) | 1994-09-01 | — | — | WO | claimed |
| WO-2026087651-A1 | CYCLOPROPANE-ARYL COMPOUNDS FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2026-04-30 | — | — | WO | disclosed |
| CN-119032076-A | Novel compounds and uses thereof | 株式会社安提昂 | 2024-11-26 | — | — | CN | disclosed |
| US-12049444-B2 | Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof | AGATHONBIO CO., LTD. (KR) | 2024-07-30 | — | — | US | disclosed |
| US-20230416460-A1 | COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED PRODUCT, AND LAMINATED SUBSTRATE | TDK CORPORATION (JP) | 2023-12-28 | — | — | US | disclosed |
| WO-2023239171-A1 | NOVEL COMPOUND AND USE THEREOF | 주식회사 엑티브온 | 2023-12-14 | — | — | WO | disclosed |
| CN-116490355-A | Compound, resin composition, resin sheet, resin cured product, and laminated substrate | TDK株式会社 | 2023-07-25 | — | — | CN | disclosed |
| WO-2022209495-A1 | COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED OBJECT, AND LAMINATED SUBSTRATE | TDK株式会社 | 2022-10-06 | — | — | WO | disclosed |
| US-20210387939-A1 | MONOMETHYL FUMARATE PRECURSOR DRUG COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | AGATHONBIO CO., LTD. (KR) | 2021-12-16 | — | — | US | disclosed |
| EP-0386639-B1 | Process for preparing para-hydroxybenzyl alcohol | MITSUBISHI PETROCHEMICAL CO (JP) | 1994-09-28 | — | — | EP | disclosed |
| WO-1994019724-A1 | NOVEL MATRIX RESIN FOR HIGH-TEMPERATURE STABLE PHOTOIMAGEABLE COMPOSITIONS | HOECHST CELANESE CORPORATION (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0485613-A1 | PROCESS FOR PARA-METHYLOLATING PHENOLIC COMPOUND | MITSUBISHI CHEMICAL CORPORATION (JP) | 1992-05-20 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-5019656-A | Hydroxymethylation of a Phenol, Basic Catalyst, Crown Compound | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1991-05-28 | — | — | US | disclosed |
| EP-0386639-A1 | Process for preparing para-hydroxybenzyl alcohol | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387939-A1 | MONOMETHYL FUMARATE PRECURSOR DRUG COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, FPGS, FAH | ESR2 3315/4885ESR1 3368/4885TYR 4110/4885 |
| US-12049444-B2 | Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof | FH, FPGS, FAH | ESR2 3315/4885ESR1 3368/4885TYR 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.